載入...
Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany
BACKGROUND: Multiple sclerosis (MS), a progressive neurodegenerative disease, greatly impacts the quality of life and economic status of people affected by this disease. In Germany, the total annual cost of MS is estimated at €40,000 per person with MS. Natalizumab has shown to slow MS disease progr...
Na minha lista:
| 發表在: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5293187/ https://ncbi.nlm.nih.gov/pubmed/28203098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S117962 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|